Karel Pacak

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/4091175/publications.pdf

Version: 2024-02-01

497 papers	36,219 citations	2795 94 h-index	4750 169 g-index
509 all docs	509 docs citations	509 times ranked	19871 citing authors

#	Article	IF	Citations
1	Pheochromocytoma and Paraganglioma: An Endocrine Society Clinical Practice Guideline. Journal of Clinical Endocrinology and Metabolism, 2014, 99, 1915-1942.	1.8	2,031
2	Phaeochromocytoma. Lancet, The, 2005, 366, 665-675.	6.3	1,462
3	Biochemical Diagnosis of Pheochromocytoma. JAMA - Journal of the American Medical Association, 2002, 287, 1427-34.	3.8	994
4	Irisin and FGF21 Are Cold-Induced Endocrine Activators of Brown Fat Function in Humans. Cell Metabolism, 2014, 19, 302-309.	7.2	643
5	Cushingâ€™s Syndrome Due to Ectopic Corticotropin Secretion: Twenty Yearsâ€™ Experience at the National Institutes of Health. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 4955-4962.	1.8	588
6	Pheochromocytoma: recommendations for clinical practice from the First International Symposium. Nature Clinical Practice Endocrinology and Metabolism, 2007, 3, 92-102.	2.9	581
7	Comprehensive Molecular Characterization of Pheochromocytoma and Paraganglioma. Cancer Cell, 2017, 31, 181-193.	7.7	532
8	Recent Advances in Genetics, Diagnosis, Localization, and Treatment of Pheochromocytoma. Annals of Internal Medicine, 2001, 134, 315.	2.0	512
9	Preoperative Management of the Pheochromocytoma Patient. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 4069-4079.	1.8	497
10	The North American Neuroendocrine Tumor Society Consensus Guideline for the Diagnosis and Management of Neuroendocrine Tumors. Pancreas, 2010, 39, 775-783.	0.5	493
11	An immunohistochemical procedure to detect patients with paraganglioma and phaeochromocytoma with germline SDHB, SDHC, or SDHD gene mutations: a retrospective and prospective analysis. Lancet Oncology, The, 2009, 10, 764-771.	5.1	477
12	Biochemical Diagnosis of Pheochromocytoma: How to Distinguish True- from False-Positive Test Results. Journal of Clinical Endocrinology and Metabolism, 2003, 88, 2656-2666.	1.8	447
13	Clinical and molecular genetics of patients with the Carneyâ€“Stratakis syndrome and germline mutations of the genes coding for the succinate dehydrogenase subunits SDHB, SDHC, and SDHD. European Journal of Human Genetics, 2008, 16, 79-88.	1.4	446
14	Mapping of human brown adipose tissue in lean and obese young men. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 8649-8654.	3.3	370
15	Comparison of 18F-Fluoro-L-DOPA, 18F-Fluoro-Deoxyglucose, and 18F-Fluorodopamine PET and 123I-MIBG Scintigraphy in the Localization of Pheochromocytoma and Paraganglioma. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 4757-4767.	1.8	361
16	Stress-Induced Norepinephrine Release in the Hypothalamic Paraventricular Nucleus and Pituitary-Adrenocortical and Sympathoadrenal Activity: In Vivo Microdialysis Studies. Frontiers in Neuroendocrinology, 1995, 16, 89-150.	2.5	348
17	SomaticHIF2AGain-of-Function Mutations in Paraganglioma with Polycythemia. New England Journal of Medicine, 2012, 367, 922-930.	13.9	338
18	Superiority of Fluorodeoxyglucose Positron Emission Tomography to Other Functional Imaging Techniques in the Evaluation of Metastatic SDHB-Associated Pheochromocytoma and Paraganglioma. Journal of Clinical Oncology, 2007, 25, 2262-2269.	0.8	316

#	Article	IF	Citations
19	Plasma methoxytyramine: A novel biomarker of metastatic pheochromocytoma and paraganglioma in relation to established risk factors of tumour size, location and SDHB mutation status. European Journal of Cancer, 2012, 48, 1739-1749.	1.3	304
20	Malignant pheochromocytoma: current status and initiatives for future progress. Endocrine-Related Cancer, 2004, 11, 423-436.	1.6	299
21	High Frequency ofSDHBGermline Mutations in Patients with Malignant Catecholamine-Producing Paragangliomas: Implications for Genetic Testing. Journal of Clinical Endocrinology and Metabolism, 2006, 91, 4505-4509.	1.8	299
22	Current Approaches and Recommended Algorithm for the Diagnostic Localization of Pheochromocytoma. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 479-491.	1.8	296
23	Molecular Subtypes ofKIT/PDGFRAWild-Type Gastrointestinal Stromal Tumors. JAMA Oncology, 2016, 2, 922.	3.4	291
24	Succinate Dehydrogenase Mutation Underlies Global Epigenomic Divergence in Gastrointestinal Stromal Tumor. Cancer Discovery, 2013, 3, 648-657.	7.7	288
25	Prospective Study of ⁶⁸Ga-DOTATATE Positron Emission Tomography/Computed Tomography for Detecting Gastro-Entero-Pancreatic Neuroendocrine Tumors and Unknown Primary Sites. Journal of Clinical Oncology, 2016, 34, 588-596.	0.8	287
26	Measurements of Plasma Methoxytyramine, Normetanephrine, and Metanephrine as Discriminators of Different Hereditary Forms of Pheochromocytoma. Clinical Chemistry, 2011, 57, 411-420.	1.5	282
27	MAX Mutations Cause Hereditary and Sporadic Pheochromocytoma and Paraganglioma. Clinical Cancer Research, 2012, 18, 2828-2837.	3.2	277
28	Pheochromocytomas in von Hippel-Lindau Syndrome and Multiple Endocrine Neoplasia Type 2 Display Distinct Biochemical and Clinical Phenotypes. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 1999-2008.	1.8	262
29	Clinical Presentations, Biochemical Phenotypes, and Genotype-Phenotype Correlations in Patients withSuccinate Dehydrogenase Subunit B-Associated Pheochromocytomas and Paragangliomas. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 779-786.	1.8	262
30	New Perspectives on Pheochromocytoma and Paraganglioma: Toward a Molecular Classification. Endocrine Reviews, 2017, 38, 489-515.	8.9	241
31	Staging and Functional Characterization of Pheochromocytoma and Paraganglioma by 18F-Fluorodeoxyglucose (18F-FDG) Positron Emission Tomography. Journal of the National Cancer Institute, 2012, 104, 700-708.	3.0	240
32	Superiority of 6-[18F]-Fluorodopamine Positron Emission TomographyVersus[131I]-Metaiodobenzylguanidine Scintigraphy in the Localization of Metastatic Pheochromocytoma. Journal of Clinical Endocrinology and Metabolism, 2003, 88, 4083-4087.	1.8	237
33	Treatment of malignant pheochromocytoma/paraganglioma with cyclophosphamide, vincristine, and dacarbazine. Cancer, 2008, 113, 2020-2028.	2.0	234
34	EANM 2012 guidelines for radionuclide imaging of phaeochromocytoma and paraganglioma. European Journal of Nuclear Medicine and Molecular Imaging, 2012, 39, 1977-1995.	3.3	223
35	Superiority of [68Ga]-DOTATATE PET/CT to Other Functional Imaging Modalities in the Localization of SDHB-Associated Metastatic Pheochromocytoma and Paraganglioma. Clinical Cancer Research, 2015, 21, 3888-3895.	3.2	223
36	The optimal imaging of adrenal tumours: a comparison of different methods. Endocrine-Related Cancer, 2007, 14, 587-599.	1.6	218

#	Article	IF	Citations
37	6-[¹⁸ F]Fluorodopamine Positron Emission Tomographic (PET) Scanning for Diagnostic Localization of Pheochromocytoma. Hypertension, 2001, 38, 6-8.	1.3	215
38	Biochemical and Clinical Manifestations of Dopamine-Producing Paragangliomas: Utility of Plasma Methoxytyramine. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 2068-2075.	1.8	213
39	Succinate Dehydrogenase Kidney Cancer: An Aggressive Example of the Warburg Effect in Cancer. Journal of Urology, 2012, 188, 2063-2071.	0.2	211
40	European Association of Nuclear Medicine Practice Guideline/Society of Nuclear Medicine and Molecular Imaging Procedure Standard 2019 for radionuclide imaging of phaeochromocytoma and paraganglioma. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 2112-2137.	3.3	208
41	Mitochondrial Complex II: At the Crossroads. Trends in Biochemical Sciences, 2017, 42, 312-325.	3.7	192
42	Reactivation of Dihydroorotate Dehydrogenase-Driven Pyrimidine Biosynthesis Restores Tumor Growth of Respiration-Deficient Cancer Cells. Cell Metabolism, 2019, 29, 399-416.e10.	7.2	190
43	Genetics, diagnosis, management and future directions of research of phaeochromocytoma and paraganglioma: a position statement and consensus of the Working Group on Endocrine Hypertension of the European Society of Hypertension. Journal of Hypertension, 2020, 38, 1443-1456.	0.3	190
44	Monoamine Oxidase Aâ€“Mediated Enhanced Catabolism of Norepinephrine Contributes to Adverse Remodeling and Pump Failure in Hearts With Pressure Overload. Circulation Research, 2010, 106, 193-202.	2.0	187
45	Current Treatment of Malignant Pheochromocytoma. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 1217-1225.	1.8	180
46	Pheochromocytoma Catecholamine Phenotypes and Prediction of Tumor Size and Location by Use of Plasma Free Metanephrines. Clinical Chemistry, 2005, 51, 735-744.	1.5	177
47	SDHB/SDHA immunohistochemistry in pheochromocytomas and paragangliomas: a multicenter interobserver variation analysis using virtual microscopy: a Multinational Study of the European Network for the Study of Adrenal Tumors (ENS@T). Modern Pathology, 2015, 28, 807-821.	2.9	176
48	The Molecular Pathogenesis of Hereditary and Sporadic Adrenocortical and Adrenomedullary Tumors. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 5367-5384.	1.8	174
49	Metastatic Pheochromocytoma/Paraganglioma Related to Primary Tumor Development in Childhood or Adolescence: Significant Link to SDHB Mutations. Journal of Clinical Oncology, 2011, 29, 4137-4142.	0.8	170
50	Catecholamine metabolomic and secretory phenotypes in phaeochromocytoma. Endocrine-Related Cancer, 2010, 18, 97-111.	1.6	169
51	Pheochromocytoma and paraganglioma: Diagnosis, genetics, management, and treatment. Current Problems in Cancer, 2014, 38, 7-41.	1.0	163
52	Understanding catecholamine metabolism as a guide to the biochemical diagnosis of pheochromocytoma. Reviews in Endocrine and Metabolic Disorders, 2001, 2, 297-311.	2.6	156
53	A novel EPAS1/HIF2A germline mutation in a congenital polycythemia with paraganglioma. Journal of Molecular Medicine, 2013, 91, 507-512.	1.7	155
54	Hypertension in Pheochromocytoma: Characteristics andÂTreatment. Endocrinology and Metabolism Clinics of North America, 2011, 40, 295-311.	1.2	153

#	Article	IF	Citations
55	Paternal versus maternal transmission of a stimulatory G-protein Î± subunit knockout produces opposite effects on energy metabolism. Journal of Clinical Investigation, 2000, 105, 615-623.	3.9	151
56	⁶⁸Ga-DOTATATE PET/CT in the Localization of Head and Neck Paragangliomas Compared with Other Functional Imaging Modalities and CT/MRI. Journal of Nuclear Medicine, 2016, 57, 186-191.	2.8	148
57	Hypoxia-Inducible Factor Signaling in Pheochromocytoma: Turning the Rudder in the Right Direction. Journal of the National Cancer Institute, 2013, 105, 1270-1283.	3.0	146
58	Functional Imaging of Endocrine Tumors: Role of Positron Emission Tomography. Endocrine Reviews, 2004, 25, 568-580.	8.9	145
59	Endocrine Withdrawal Syndromes. Endocrine Reviews, 2003, 24, 523-538.	8.9	144
60	Loss of Meal-Induced Decrease in Plasma Ghrelin Levels in Patients with Anorexia Nervosa. Journal of Clinical Endocrinology and Metabolism, 2003, 88, 1678-1682.	1.8	142
61	Effects of Various Stressors on In Vivo Norepinephrine Release in the Hypothalamic Paraventricular Nucleus and on the Pituitary-Adrenocortical Axis. Annals of the New York Academy of Sciences, 1995, 771, 115-130.	1.8	141
62	Usefulness of ¹²³I-MIBG Scintigraphy in the Evaluation of Patients with Known or Suspected Primary or Metastatic Pheochromocytoma or Paraganglioma: Results from a Prospective Multicenter Trial. Journal of Nuclear Medicine, 2009, 50, 1448-1454.	2.8	139
63	PET/CT comparing 68Ga-DOTATATE and other radiopharmaceuticals and in comparison with CT/MRI for the localization of sporadic metastatic pheochromocytoma and paraganglioma. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 1784-1791.	3.3	138
64	Comparison of 6-¹⁸F-Fluorodopamine PET with ¹²³I-Metaiodobenzylguanidine and ¹¹¹In-Pentetreotide Scintigraphy in Localization of Nonmetastatic and Metastatic Pheochromocytoma. Journal of Nuclear Medicine, 2008, 49, 1613-1619.	2.8	137
65	Landscape of the mitochondrial Hsp90 metabolome in tumours. Nature Communications, 2013, 4, 2139.	5.8	135
66	Monoamine Oxidase B Prompts Mitochondrial and Cardiac Dysfunction in Pressure Overloaded Hearts. Antioxidants and Redox Signaling, 2014, 20, 267-280.	2.5	135
67	Succinate Dehydrogenase (SDH) D Subunit (SDHD) Inactivation in a Growth-Hormone-Producing Pituitary Tumor: A New Association for SDH?. Journal of Clinical Endocrinology and Metabolism, 2012, 97, E357-E366.	1.8	134
68	The Role of [18F]Fluorodeoxyglucose Positron Emission Tomography and [111In]-Diethylenetriaminepentaacetate-d-Phe-Pentetreotide Scintigraphy in the Localization of Ectopic Adrenocorticotropin-Secreting Tumors Causing Cushingâ€™s Syndrome. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 2214-2221.	1.8	133
69	Functional Imaging ofSDHx-Related Head and Neck Paragangliomas: Comparison of¹⁸F-Fluorodihydroxyphenylalanine,¹⁸F-Fluorodopamine,¹⁸F-Fluoro-2-Deoxy-<scp>d</scp>-Glu PET,¹²³I-Metaiodobenzylguanidine Scintigraphy, and¹¹¹In-Pentetreotide Scintigraphy. Journal of Clinical Endocrinology and Metabolism, 2011, 96, 2779-2785.	1.8	129
70	New Syndrome of Paraganglioma and Somatostatinoma Associated With Polycythemia. Journal of Clinical Oncology, 2013, 31, 1690-1698.	0.8	129
71	Personalized Management of Pheochromocytoma and Paraganglioma. Endocrine Reviews, 2022, 43, 199-239.	8.9	127
72	Current Approaches and Recent Developments in the Management of Head and Neck Paragangliomas. Endocrine Reviews, 2014, 35, 795-819.	8.9	124

#	Article	IF	Citations
73	Adverse Drug Reactions in Patients with Phaeochromocytoma. Drug Safety, 2007, 30, 1031-1062.	1.4	122
74	Pituitary Adenoma With Paraganglioma/Pheochromocytoma (3PAs) and Succinate Dehydrogenase Defects in Humans and Mice. Journal of Clinical Endocrinology and Metabolism, 2015, 100, E710-E719.	1.8	121
75	Characteristics of Pediatric vs Adult Pheochromocytomas and Paragangliomas. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 1122-1132.	1.8	120
76	Current Management of Pheochromocytoma/Paraganglioma: A Guide for the Practicing Clinician in the Era of Precision Medicine. Cancers, 2019, 11, 1505.	1.7	120
77	Heterogeneous neurochemical responses to different stressors: a test of Selyeâ€™s doctrine of nonspecificity. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 1998, 275, R1247-R1255.	0.9	119
78	Molecular Imaging of Gastroenteropancreatic Neuroendocrine Tumors: Current Status and Future Directions. Journal of Nuclear Medicine, 2016, 57, 1949-1956.	2.8	119
79	Central Nervous System Imprinting of the G Protein GsÎ± and Its Role in Metabolic Regulation. Cell Metabolism, 2009, 9, 548-555.	7.2	118
80	Germ-line PHD1 and PHD2 mutations detected in patients with pheochromocytoma/paraganglioma-polycythemia. Journal of Molecular Medicine, 2015, 93, 93-104.	1.7	118
81	Clinical aspects of SDHx-related pheochromocytoma and paraganglioma. Endocrine-Related Cancer, 2009, 16, 391-400.	1.6	117
82	Biochemical Diagnosis and Localization of Pheochromocytoma: Can We Reach a Consensus?. Annals of the New York Academy of Sciences, 2006, 1073, 332-347.	1.8	115
83	New imaging approaches to phaeochromocytomas and paragangliomas. Clinical Endocrinology, 2010, 72, 137-145.	1.2	112
84	Biochemically Silent Abdominal Paragangliomas in Patients with Mutations in theSuccinate Dehydrogenase Subunit BGene. Journal of Clinical Endocrinology and Metabolism, 2008, 93, 4826-4832.	1.8	111
85	Krebs Cycle Metabolite Profiling for Identification and Stratification of Pheochromocytomas/Paragangliomas due to Succinate Dehydrogenase Deficiency. Journal of Clinical Endocrinology and Metabolism, 2014, 99, 3903-3911.	1.8	111
86	Noradrenergic activation in the paraventricular nucleus during acute and chronic immobilization stress in rats: an in vivo microdialysis study. Brain Research, 1992, 589, 91-96.	1.1	110
87	Is Supine Rest Necessary before Blood Sampling for Plasma Metanephrines?. Clinical Chemistry, 2007, 53, 352-354.	1.5	110
88	Characteristics And Outcomes Of Metastatic Sdhb And Sporadic Pheochromocytoma/Paraganglioma: An National Institutes Of Health Study. Endocrine Practice, 2016, 22, 302-314.	1.1	110
89	False-negative 123I-MIBG SPECT is most commonly found in SDHB-related pheochromocytoma or paraganglioma with high frequency to develop metastatic disease. Endocrine-Related Cancer, 2012, 19, 83-93.	1.6	106
90	Plasma Metadrenalines: Do they Provide Useful Information about Sympatho-Adrenal Function and Catecholamine Metabolism?. Clinical Science, 1995, 88, 533-542.	1.8	105

#	Article	IF	Citations
91	Utility of Plasma Free Metanephrines for Detecting Childhood Pheochromocytoma. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 1955-1960.	1.8	104
92	Update on pediatric pheochromocytoma. Pediatric Nephrology, 2009, 24, 943-950.	0.9	102
93	The Effects of Carbidopa on Uptake of 6-18F-Fluoro-L-DOPA in PET of Pheochromocytoma and Extraadrenal Abdominal Paraganglioma. Journal of Nuclear Medicine, 2007, 48, 1599-1606.	2.8	101
94	Reference intervals for plasma free metanephrines with an age adjustment for normetanephrine for optimized laboratory testing of phaeochromocytoma. Annals of Clinical Biochemistry, 2013, 50, 62-69.	0.8	98
95	Prospective comparison of 68Ga-DOTATATE and 18F-FDOPA PET/CT in patients with various pheochromocytomas and paragangliomas with emphasis on sporadic cases. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 1248-1257.	3.3	96
96	Drugs and Pheochromocytoma â€" Don't Be Fooled by Every Elevated Metanephrine. New England Journal of Medicine, 2011, 364, 2268-2270.	13.9	95
97	New Roles of Carboxypeptidase E in Endocrine and Neural Function and Cancer. Endocrine Reviews, 2012, 33, 216-253.	8.9	95
98	Effects of immobilization on in vivo release of norepinephrine in the bed nucleus of the stria terminalis in conscious rats. Brain Research, 1995, 688, 242-246.	1.1	92
99	Downregulation of metastasis suppressor genes in malignant pheochromocytoma. International Journal of Cancer, 2005, 114, 139-143.	2.3	92
100	Brown Fat Imaging with 18F-6-Fluorodopamine PET/CT, 18F-FDG PET/CT, and 123I-MIBG SPECT: A Study of Patients Being Evaluated for Pheochromocytoma. Journal of Nuclear Medicine, 2007, 48, 1077-1083.	2.8	92
101	Metastatic Paraganglioma. Seminars in Oncology, 2010, 37, 627-637.	0.8	91
102	Age at Diagnosis of Pheochromocytoma Differs According to Catecholamine Phenotype and Tumor Location. Journal of Clinical Endocrinology and Metabolism, 2011, 96, 375-384.	1.8	90
103	Cardiac sympathetic denervation preceding motor signs in Parkinson disease. Clinical Autonomic Research, 2007, 17, 118-121.	1.4	88
104	Pheochromocytoma as an endocrine emergency. Reviews in Endocrine and Metabolic Disorders, 2003, 4, 121-128.	2.6	87
105	Novel HIF2A mutations disrupt oxygen sensing, leading to polycythemia, paragangliomas, and somatostatinomas. Blood, 2013, 121, 2563-2566.	0.6	87
106	Genotypeâ€"phenotype correlations in pheochromocytoma and paraganglioma: a systematic review and individual patient meta-analysis. Endocrine-Related Cancer, 2019, 26, 539-550.	1.6	87
107	Pheochromocytoma crisis induced by glucocorticoids: a report of four cases and review of the literature. European Journal of Endocrinology, 2008, 158, 423-429.	1.9	86
108	Discordant localization of 2-[18F]-fluoro-2-deoxy-D-glucose in 6-[18F]-fluorodopamine- and [123I]-metaiodobenzylguanidine-negative metastatic pheochromocytoma sites. Nuclear Medicine Communications, 2006, 27, 31-36.	0.5	85

#	Article	IF	Citations
109	Partial Adrenalectomy: Underused First Line Therapy for Small Adrenal Tumors. Journal of Urology, 2010, 184, 18-25.	0.2	85
110	15 YEARS OF PARAGANGLIOMA: Imaging and imaging-based treatment of pheochromocytoma and paraganglioma. Endocrine-Related Cancer, 2015, 22, T135-T145.	1.6	84
111	Radiofrequency Ablation: a Novel Approach for Treatment of Metastatic Pheochromocytoma. Journal of the National Cancer Institute, 2001, 93, 648-649.	3.0	83
112	Update of Pheochromocytoma Syndromes: Genetics, Biochemical Evaluation, and Imaging. Frontiers in Endocrinology, 2018, 9, 515.	1.5	82
113	Minimal changes in environmental temperature result in a significant increase in energy expenditure and changes in the hormonal homeostasis in healthy adults. European Journal of Endocrinology, 2010, 163, 863-872.	1.9	80
114	International consensus on initial screening and follow-up of asymptomatic SDHx mutation carriers. Nature Reviews Endocrinology, 2021, 17, 435-444.	4.3	80
115	Accuracy of recommended sampling and assay methods for the determination of plasma-free and urinary fractionated metanephrines in the diagnosis of pheochromocytoma and paraganglioma: a systematic review. Endocrine, 2017, 56, 495-503.	1.1	79
116	Impaired Basal and Restraint-Induced Epinephrine Secretion in Corticotropin-Releasing Hormone-Deficient Mice¹. Endocrinology, 2000, 141, 1142-1150.	1.4	78
117	The role of 6-[18F]fluorodopamine positron emission tomography in the localization of adrenal pheochromocytoma associated with von Hippelâ€“Lindau syndrome. European Journal of Endocrinology, 2007, 156, 483-487.	1.9	78
118	SDH-related pheochromocytoma and paraganglioma. Best Practice and Research in Clinical Endocrinology and Metabolism, 2010, 24, 415-424.	2.2	78
119	Subclinical phaeochromocytoma. Best Practice and Research in Clinical Endocrinology and Metabolism, 2012, 26, 507-515.	2.2	76
120	Pheochromocytoma in von Hippel-Lindau Disease: Distinct Histopathologic Phenotype Compared to Pheochromocytoma in Multiple Endocrine Neoplasia Type 2. Endocrine Pathology, 2002, 13, 17-28.	5.2	74
121	Use of 6â€[¹⁸F]â€fluorodopamine positron emission tomography (PET) as firstâ€line investigation for the diagnosis and localization of nonâ€metastatic and metastatic phaeochromocytoma (PHEO). Clinical Endocrinology, 2009, 71, 11-17.	1.2	74
122	Plasma metanephrines in renal failure. Kidney International, 2005, 67, 668-677.	2.6	73
123	Opposing effects of HIF1Î± and HIF2Î± on chromaffin cell phenotypic features and tumor cell proliferation: Insights from MYCâ€associated factor X. International Journal of Cancer, 2014, 135, 2054-2064.	2.3	72
124	Results of 68Gallium-DOTATATE PET/CT Scanning in Patients with Multiple Endocrine Neoplasia Type 1. Journal of the American College of Surgeons, 2015, 221, 509-517.	0.2	72
125	Molecular imaging and radionuclide therapy of pheochromocytoma and paraganglioma in the era of genomic characterization of disease subgroups. Endocrine-Related Cancer, 2019, 26, R627-R652.	1.6	72
126	Genomic Landscape of Pheochromocytoma and Paraganglioma. Trends in Cancer, 2018, 4, 6-9.	3.8	71

#	Article	IF	Citations
127	CRH Deficiency Impairs but Does Not Block Pituitary-Adrenal Responses to Diverse Stressors. Neuroendocrinology, 2000, 71, 79-87.	1.2	68
128	New Advances in the Biochemical Diagnosis of Pheochromocytoma. Annals of the New York Academy of Sciences, 2002, 970, 29-40.	1.8	68
129	Correlation Between In Vivo ¹⁸F-FDG PET and Immunohistochemical Markers of Glucose Uptake and Metabolism in Pheochromocytoma and Paraganglioma. Journal of Nuclear Medicine, 2014, 55, 1253-1259.	2.8	67
130	Differential expression of the regulated catecholamine secretory pathway in different hereditary forms of pheochromocytoma. American Journal of Physiology - Endocrinology and Metabolism, 2008, 295, E1223-E1233.	1.8	66
131	Functional and Oncologic Outcomes of Partial Adrenalectomy for Pheochromocytoma in Patients With von Hippel-Lindau Syndrome After at Least 5 Years of Followup. Journal of Urology, 2010, 184, 1855-1859.	0.2	66
132	Histone deacetylase inhibitors increase glucocerebrosidase activity in Gaucher disease by modulation of molecular chaperones. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 966-971.	3.3	66
133	New functional imaging modalities for chromaffin tumors, neuroblastomas and ganglioneuromas. Trends in Endocrinology and Metabolism, 2005, 16, 66-72.	3.1	65
134	Emergencies Caused by Pheochromocytoma, Neuroblastoma, or Ganglioneuroma. Endocrinology and Metabolism Clinics of North America, 2006, 35, 699-724.	1.2	65
135	Effects of Single or Repeated Immobilization on Release of Norepinephrine and Its Metabolites in the Central Nucleus of the Amygdala in Conscious Rats. Neuroendocrinology, 1993, 57, 626-633.	1.2	64
136	Interrelations between Sympathoadrenal System andHypothalamo-Pituitary-Adrenocortical/Thyroid Systemsin Rats Exposed to Cold Stress. Journal of Neuroendocrinology, 1996, 8, 533-541.	1.2	64
137	INCREASED PLASMA NOREPINEPHRINE CONCENTRATION IN CATS WITH INTERSTITIAL CYSTITIS. Journal of Urology, 2001, 165, 2051-2054.	0.2	64
138	Localization of Medullary Thyroid Carcinoma Metastasis in a Multiple Endocrine Neoplasia Type 2A Patient by 6-[18F]-Fluorodopamine Positron Emission Tomography. Journal of Clinical Endocrinology and Metabolism, 2003, 88, 637-641.	1.8	64
139	A clinical overview of pheochromocytomas/paragangliomas and carcinoid tumors. Nuclear Medicine and Biology, 2008, 35, S27-S34.	0.3	64
140	Superiority of 68Ga-DOTATATE over 18F-FDG and anatomic imaging in the detection of succinate dehydrogenase mutation (SDHx)-related pheochromocytoma and paraganglioma in the pediatric population. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 787-797.	3.3	64
141	Vorinostat suppresses hypoxia signaling by modulating nuclear translocation of hypoxia inducible factor 1 alpha. Oncotarget, 2017, 8, 56110-56125.	0.8	64
142	Succinate-to-Fumarate Ratio as a New Metabolic Marker to Detect the Presence of SDHB/D-related Paraganglioma: Initial Experimental and Ex Vivo Findings. Endocrinology, 2014, 155, 27-32.	1.4	63
143	SDHB-related pheochromocytoma and paraganglioma penetrance and genotypeâ€“phenotype correlations. Journal of Cancer Research and Clinical Oncology, 2017, 143, 1421-1435.	1.2	63
144	PheoSeq. Journal of Molecular Diagnostics, 2017, 19, 575-588.	1.2	63

#	Article	IF	Citations
145	Stress-Induced Norepinephrine Release in the Paraventricular Nucleus of Rats with Brainstem Hemisections: A Microdialysis Study. Neuroendocrinology, 1993, 58, 196-201.	1.2	62
146	Characterization of an animal model of aggressive metastatic pheochromocytoma linked to a specific gene signature. Clinical and Experimental Metastasis, 2009, 26, 239-250.	1.7	62
147	Novel insights into the polycythemiaâ€“paragangliomaâ€“somatostatinoma syndrome. Endocrine-Related Cancer, 2016, 23, 899-908.	1.6	62
148	Prognostic Utility of Total 68Ga-DOTATATE-Avid Tumor Volume in Patients With Neuroendocrine Tumors. Gastroenterology, 2018, 154, 998-1008.e1.	0.6	62
149	Current Role of Metaiodobenzylguanidine in the Diagnosis of Pheochromocytoma and Medullary Thyroid Cancer. Seminars in Nuclear Medicine, 2011, 41, 364-368.	2.5	61
150	An N-terminal truncated carboxypeptidase E splice isoform induces tumor growth and is a biomarker for predicting future metastasis in human cancers. Journal of Clinical Investigation, 2011, 121, 880-892.	3.9	61
151	Diagnostic Localization of Pheochromocytoma. Annals of the New York Academy of Sciences, 2002, 970, 170-176.	1.8	60
152	Role of positron emission tomography and bone scintigraphy in the evaluation of bone involvement in metastatic pheochromocytoma and paraganglioma: specific implications for succinate dehydrogenase enzyme subunit B gene mutations. Endocrine-Related Cancer, 2008, 15, 311-323.	1.6	60
153	Pheochromocytoma Screening Initiation and Frequency in von Hippel-Lindau Syndrome. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 4498-4504.	1.8	60
154	Metabolome Profiling by HRMAS NMR Spectroscopy of Pheochromocytomas and Paragangliomas Detects SDH Deficiency: Clinical and Pathophysiological Implications. Neoplasia, 2015, 17, 55-65.	2.3	60
155	SDHB mutation status and tumor size but not tumor grade are important predictors of clinical outcome in pheochromocytoma and abdominal paraganglioma. Surgery, 2017, 161, 230-239.	1.0	60
156	Metabolome-guided genomics to identify pathogenic variants in isocitrate dehydrogenase, fumarate hydratase, and succinate dehydrogenase genes in pheochromocytoma and paraganglioma. Genetics in Medicine, 2019, 21, 705-717.	1.1	60
157	Gene Expression Profiling of Benign and Malignant Pheochromocytoma. Annals of the New York Academy of Sciences, 2006, 1073, 541-556.	1.8	59
158	Pheochromocytoma: The First Metabolic Endocrine Cancer. Clinical Cancer Research, 2016, 22, 5001-5011.	3.2	59
159	Pheochromocytoma and Paraganglioma. Progress in Brain Research, 2010, 182, 343-373.	0.9	58
160	Surgical Management of Wild-Type Gastrointestinal Stromal Tumors: A Report From the National Institutes of Health Pediatric and Wildtype GIST Clinic. Journal of Clinical Oncology, 2017, 35, 523-528.	0.8	58
161	Precision Medicine: An Update on Genotype/Biochemical Phenotype Relationships in Pheochromocytoma/Paraganglioma Patients. Endocrine Practice, 2017, 23, 690-704.	1.1	58
162	Different expression of catecholamine transporters in phaeochromocytomas from patients with von Hippel-Lindau syndrome and multiple endocrine neoplasia type 2. European Journal of Endocrinology, 2005, 153, 551-563.	1.9	57

#	Article	IF	Citations
163	Carney triad can be (rarely) associated with germline succinate dehydrogenase defects. European Journal of Human Genetics, 2016, 24, 569-573.	1.4	57
164	Targeting NAD+/PARP DNA Repair Pathway as a Novel Therapeutic Approach to SDHB-Mutated Cluster I Pheochromocytoma and Paraganglioma. Clinical Cancer Research, 2018, 24, 3423-3432.	3.2	57
165	Genetic Testing for Pheochromocytoma. Current Hypertension Reports, 2010, 12, 456-464.	1.5	56
166	The size of the primary tumor and age at initial diagnosis are independent predictors of the metastatic behavior and survival of patients with SDHB-related pheochromocytoma and paraganglioma: a retrospective cohort study. BMC Cancer, 2014, 14, 523.	1.1	55
167	New Insights into the Genetics of Familial Chromaffin Cell Tumors. Annals of the New York Academy of Sciences, 2002, 970, 11-28.	1.8	54
168	Biochemical Diagnosis of Pheochromocytoma. , 2003, 31, 76-106.		54
169	First Report of Bilateral Pheochromocytoma in the Clinical Spectrum ofHIF2A-Related Polycythemia-Paraganglioma Syndrome. Journal of Clinical Endocrinology and Metabolism, 2013, 98, E908-E913.	1.8	54
170	Pheochromocytoma and Paraganglioma. Endocrine Practice, 2015, 21, 406-412.	1.1	54
171	Genotype-Specific Abnormalities in Mitochondrial Function Associate with Distinct Profiles of Energy Metabolism and Catecholamine Content in Pheochromocytoma and Paraganglioma. Clinical Cancer Research, 2013, 19, 3787-3795.	3.2	53
172	Protocol for the Examination of Specimens From Patients With Pheochromocytomas and Extra-Adrenal Paragangliomas. Archives of Pathology and Laboratory Medicine, 2014, 138, 182-188.	1.2	52
173	A â€œPheoâ€•Lurks: Novel Approaches for Locating Occult Pheochromocytoma. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 3641-3646.	1.8	51
174	Radiofrequency Ablation of Metastatic Pheochromocytoma. Journal of Vascular and Interventional Radiology, 2009, 20, 1483-1490.	0.2	51
175	Genetics of pheochromocytoma and paraganglioma syndromes. Current Opinion in Endocrinology, Diabetes and Obesity, 2013, 20, 186-191.	1.2	51
176	External Beam Radiation Therapy in Treatment of Malignant Pheochromocytoma and Paraganglioma. Frontiers in Oncology, 2014, 4, 166.	1.3	51
177	Catecholamine-Induced Cardiomyopathy in Pheochromocytoma: How to Manage a Rare Complication in a Rare Disease?. Hormone and Metabolic Research, 2019, 51, 458-469.	0.7	51
178	Laparoscopic Management of Extra-Adrenal Pheochromocytoma. Journal of Urology, 2004, 171, 72-76.	0.2	50
179	Current Trends in Functional Imaging of Pheochromocytomas and Paragangliomas. Annals of the New York Academy of Sciences, 2006, 1073, 374-382.	1.8	50
180	The Presence of SDHB Mutations Should Modify Surgical Indications for Carotid Body Paragangliomas. Annals of Surgery, 2014, 260, 158-162.	2.1	50

#	Article	IF	Citations
181	Imaging of Pheochromocytoma and Paraganglioma. Journal of Nuclear Medicine, 2021, 62, 1033-1042.	2.8	50
182	Functional characterization of nonmetastatic paraganglioma and pheochromocytoma by ¹⁸Fâ€<scp>FDOPA PET</scp>: focus on missed lesions. Clinical Endocrinology, 2013, 79, 170-177.	1.2	49
183	Catecholamine physiology and its implications in patients with COVID-19. Lancet Diabetes and Endocrinology,the, 2020, 8, 978-986.	5.5	49
184	Effects of Hypo- and Hyperthyroidism on Noradrenergic Activity and Glycerol Concentrations in Human Subcutaneous Abdominal Adipose Tissue Assessed with Microdialysis. Journal of Clinical Endocrinology and Metabolism, 2003, 88, 5605-5608.	1.8	48
185	Brief Communication: Radiographic Contrast Infusion and Catecholamine Release in Patients With Pheochromocytoma. Annals of Internal Medicine, 2009, 150, 27.	2.0	48
186	Familial pheochromocytomas and paragangliomas. Molecular and Cellular Endocrinology, 2014, 386, 92-100.	1.6	47
187	Pediatric patients with pheochromocytoma and paraganglioma should have routine preoperative genetic testing for common susceptibility genes in addition to imaging to detect extra-adrenal and metastatic tumors. Surgery, 2017, 161, 220-227.	1.0	47
188	Allelic imbalance of the mutant and wild-type RET allele in MEN 2A-associated medullary thyroid carcinoma. Oncogene, 2001, 20, 7809-7811.	2.6	46
189	Missense mutations in the human SDHB gene increase protein degradation without altering intrinsic enzymatic function. FASEB Journal, 2012, 26, 4506-4516.	0.2	46
190	Increased blood pressure variability in pheochromocytoma compared to essential hypertension patients. Journal of Hypertension, 2005, 23, 2033-2039.	0.3	45
191	Role of MDH2 pathogenic variant in pheochromocytoma and paraganglioma patients. Genetics in Medicine, 2018, 20, 1652-1662.	1.1	45
192	Mutations associated with succinate dehydrogenase <scp>d</scp>â€related malignant paragangliomas. Clinical Endocrinology, 2008, 68, 561-566.	1.2	44
193	Combined blockade of signalling pathways shows marked anti-tumour potential in phaeochromocytoma cell lines. Journal of Molecular Endocrinology, 2012, 49, 79-96.	1.1	44
194	Response after Surgical Resection of Metastatic Pheochromocytoma and Paraganglioma: Can Postoperative Biochemical Remission Be Predicted?. Journal of the American College of Surgeons, 2013, 217, 489-496.	0.2	44
195	Alternative assembly of respiratory complex II connects energy stress to metabolic checkpoints. Nature Communications, 2018, 9, 2221.	5.8	44
196	Adipocyte Î²-arrestin-2 is essential for maintaining whole body glucose and energy homeostasis. Nature Communications, 2019, 10, 2936.	5.8	43
197	Emerging Treatments for Advanced/Metastatic Pheochromocytoma and Paraganglioma. Current Treatment Options in Oncology, 2020, 21, 85.	1.3	43
198	Sympathoadrenal function in patients with paroxysmal hypertension: pseudopheochromocytoma. Journal of Hypertension, 2007, 25, 2286-2295.	0.3	42

#	Article	IF	Citations
199	Mediastinal paragangliomas: association with mutations in the succinate dehydrogenase genes and aggressive behavior. Endocrine-Related Cancer, 2009, 16, 291-299.	1.6	42
200	Metastatic pheochromocytoma: Does the size and age matter?. European Journal of Clinical Investigation, 2011, 41, 1121-1128.	1.7	42
201	High-Specific-Activity-131I-MIBG versus 177Lu-DOTATATE Targeted Radionuclide Therapy for Metastatic Pheochromocytoma and Paraganglioma. Clinical Cancer Research, 2021, 27, 2989-2995.	3.2	42
202	Chronic Hypercortisolemia Inhibits Dopamine Synthesis and Turnover in the Nucleus accumbens: An in vivo Microdialysis Study. Neuroendocrinology, 2002, 76, 148-157.	1.2	41
203	Combined Inhibition of mTORC1 and mTORC2 Signaling Pathways Is a Promising Therapeutic Option in Inhibiting Pheochromocytoma Tumor Growth: In Vitro and In Vivo Studies in Female Athymic Nude Mice. Endocrinology, 2013, 154, 646-655.	1.4	41
204	Diagnosis and Localization of Pheochromocytoma. Hypertension, 2004, 43, 907-910.	1.3	40
205	Anatomical and Functional Imaging of Metastatic Pheochromocytoma. Annals of the New York Academy of Sciences, 2004, 1018, 495-504.	1.8	40
206	Clinical utility of chromogranin A in <scp>SDH</scp>xâ€related paragangliomas. European Journal of Clinical Investigation, 2014, 44, 365-371.	1.7	40
207	The Genetic Basis of Pheochromocytoma and Paraganglioma: Implications for Management. Urology, 2014, 83, 1225-1232.	0.5	40
208	Metastatic Phaeochromocytoma: Spinning Towards More Promising Treatment Options. Experimental and Clinical Endocrinology and Diabetes, 2019, 127, 117-128.	0.6	40
209	The neuronal and extraneuronal origins of plasma 3-methoxy-4-hydroxyphenylglycol in rats. Journal of the Autonomic Nervous System, 1994, 50, 93-107.	1.9	39
210	The Adrenal Medulla and Extra-adrenal Paraganglia: Then and Now. Endocrine Pathology, 2014, 25, 49-58.	5.2	39
211	Clinical, Diagnostic, and Treatment Characteristics of SDHA-Related Metastatic Pheochromocytoma and Paraganglioma. Frontiers in Oncology, 2019, 9, 53.	1.3	39
212	A New Specific Succinate-Glutamate Metabolomic Hallmark in Sdhx-Related Paragangliomas. PLoS ONE, 2013, 8, e80539.	1.1	39
213	Elevated Inflammation Markers in Pheochromocytoma Compared to Other Forms of Hypertension. NeuroImmunoModulation, 2007, 14, 57-64.	0.9	38
214	GsÎ± Deficiency in Adipose Tissue Leads to a Lean Phenotype with Divergent Effects on Cold Tolerance and Diet-Induced Thermogenesis. Cell Metabolism, 2010, 11, 320-330.	7.2	38
215	In vivo micro-CT imaging of liver lesions in small animal models. Methods, 2010, 50, 20-25.	1.9	38
216	Association between neuroendocrine tumors biomarkers and primary tumor site and disease type based on total 68Ga-DOTATATE-Avid tumor volume measurements. European Journal of Endocrinology, 2017, 176, 575-582.	1.9	38

#	Article	IF	Citations
217	Glycine stimulates striatal dopamine release in conscious rats. British Journal of Pharmacology, 1993, 110, 50-53.	2.7	37
218	Increased uptake of [123I]meta-iodobenzylguanidine, [18F]fluorodopamine, and [3H]norepinephrine in mouse pheochromocytoma cells and tumors after treatment with the histone deacetylase inhibitors. Endocrine-Related Cancer, 2011, 18, 143-157.	1.6	37
219	Molecular imaging and theranostic approaches in pheochromocytoma and paraganglioma. Cell and Tissue Research, 2018, 372, 393-401.	1.5	37
220	Pheochromocytoma/paraganglioma: recent updates in genetics, biochemistry, immunohistochemistry, metabolomics, imaging and therapeutic options. Gland Surgery, 2020, 9, 105-123.	0.5	37
221	Diagnosis of pheochromocytoma with special emphasis on MEN2 syndrome. Hormones, 2009, 8, 111-116.	0.9	36
222	ZNF367 Inhibits Cancer Progression and Is Targeted by miR-195. PLoS ONE, 2014, 9, e101423.	1.1	36
223	Medullary Thyroid Carcinoma: An Update on Imaging. Journal of Thyroid Research, 2019, 2019, 1-17.	0.5	36
224	Disprocynium24, a novel inhibitor of the extraneuronal monoamine transporter, has potent effects on the inactivation of circulating noradrenaline and adrenaline in conscious rat. Naunyn-Schmiedeberg's Archives of Pharmacology, 1996, 354, 287-94.	1.4	34
225	Noninvasive monitoring of a murine model of metastatic pheochromocytoma: A comparison of contrastâ€enhanced microCT and nonenhanced MRI. Journal of Magnetic Resonance Imaging, 2009, 29, 685-691.	1.9	34
226	Factors influencing arterial stiffness in pheochromocytoma and effect of adrenalectomy. Hypertension Research, 2010, 33, 454-459.	1.5	34
227	NFâ€ºB inhibition significantly upregulates the norepinephrine transporter system, causes apoptosis in pheochromocytoma cell lines and prevents metastasis in an animal model. International Journal of Cancer, 2012, 131, 2445-2455.	2.3	34
228	Role of Hypoxia and HIF2Î± in Development of the Sympathoadrenal Cell Lineage and Chromaffin Cell Tumors with Distinct Catecholamine Phenotypic Features. Advances in Pharmacology, 2013, 68, 285-317.	1.2	34
229	Magnetic resonance spectroscopy of paragangliomas: new insights into in vivo metabolomics. Endocrine-Related Cancer, 2015, 22, M1-M8.	1.6	34
230	New Insights into the Nuclear Imaging Phenotypes of Cluster 1 Pheochromocytoma and Paraganglioma. Trends in Endocrinology and Metabolism, 2017, 28, 807-817.	3.1	34
231	Radioguided Surgery With Gallium 68 Dotatate for Patients With Neuroendocrine Tumors. JAMA Surgery, 2019, 154, 40.	2.2	34
232	Somatic VHL gene deletion and point mutation in MENâ€‰2A-associated pheochromocytoma. Oncogene, 2002, 21, 479-482.	2.6	33
233	Bilateral Adrenal Medullary Hyperplasia Associated With an SDHB Mutation. Journal of Clinical Oncology, 2011, 29, e200-e202.	0.8	33
234	Pheochromocytoma and Paraganglioma: Current Functional and Future Molecular Imaging. Frontiers in Oncology, 2011, 1, 58.	1.3	33

#	Article	IF	Citations
235	Genotype and Tumor Locus Determine Expression Profile of Pseudohypoxic Pheochromocytomas and Paragangliomas. Neoplasia, 2013, 15, 435-IN22.	2.3	33
236	Pheochromocytomas and Paragangliomas: From Genetic Diversity to Targeted Therapies. Cancers, 2019, 11, 436.	1.7	33
237	HIF2Î± supports pro-metastatic behavior in pheochromocytomas/paragangliomas. Endocrine-Related Cancer, 2020, 27, 625-640.	1.6	33
238	New Insights on the Genetics of Pheochromocytoma and Paraganglioma and Its Clinical Implications. Cancers, 2022, 14, 594.	1.7	33
239	Cerebrospinal Fluid Catecholamine Levels as Predictors of Outcome in Subarachnoid Hemorrhage. Cerebrovascular Diseases, 2012, 33, 173-181.	0.8	32
240	Warburg Effectâ€™s Manifestation in Aggressive Pheochromocytomas and Paragangliomas: Insights from a Mouse Cell Model Applied to Human Tumor Tissue. PLoS ONE, 2012, 7, e40949.	1.1	32
241	Preoperative genetic testing in pheochromocytomas and paragangliomas influences the surgical approach and the extent of adrenal surgery. Surgery, 2018, 163, 191-196.	1.0	32
242	Pharmacologic Modulation of Serine/Threonine Phosphorylation Highly Sensitizes PHEO in a MPC Cell and Mouse Model to Conventional Chemotherapy. PLoS ONE, 2011, 6, e14678.	1.1	32
243	Brainstem Hemisection Decreases Corticotropin-Releasing Hormone mRNA in the Paraventricular Nucleus but not in the Central Amygdaloid Nucleus. Journal of Neuroendocrinology, 1996, 8, 543-551.	1.2	31
244	Survivin: a novel neuroendocrine marker for pheochromocytoma. European Journal of Endocrinology, 2002, 146, 381-388.	1.9	31
245	Current views on cell metabolism in SDHx-related pheochromocytoma and paraganglioma. Endocrine-Related Cancer, 2014, 21, R261-R277.	1.6	31
246	Documenting stress in caregivers of transplantation patients: initial evidence of HPA dysregulation. Stress, 2016, 19, 175-184.	0.8	31
247	Role of CRH in Glucopenia-Induced Adrenomedullary Activation in Rats. Journal of Neuroendocrinology, 1993, 5, 475-486.	1.2	30
248	MicroCT for high-resolution imaging of ectopic pheochromocytoma tumors in the liver of nude mice. International Journal of Cancer, 2006, 119, 2236-2241.	2.3	30
249	Succinate dehydrogenase gene mutations are strongly associated with paraganglioma of the organ of Zuckerkandl. Endocrine-Related Cancer, 2010, 17, 581-588.	1.6	30
250	Murine Models and Cell Lines for the Investigation of Pheochromocytoma: Applications for Future Therapies?. Endocrine Pathology, 2012, 23, 43-54.	5.2	30
251	¹⁸Fâ€<scp>FDG PET</scp>/<scp>CT</scp> as a predictor of hereditary head and neck paragangliomas. European Journal of Clinical Investigation, 2014, 44, 325-332.	1.7	30
252	Succinate Dehydrogenase Gene Mutations in Cardiac Paragangliomas. American Journal of Cardiology, 2015, 115, 1753-1759.	0.7	30

#	Article	IF	Citations
253	Pathophysiology and Acute Management of Tachyarrhythmias in Pheochromocytoma. Journal of the American College of Cardiology, 2020, 76, 451-464.	1.2	30
254	Clinical characteristics and outcomes of SDHB-related pheochromocytoma and paraganglioma in children and adolescents. Journal of Cancer Research and Clinical Oncology, 2020, 146, 1051-1063.	1.2	30
255	Somatic VHLgene alterations in MEN2-associated medullary thyroid carcinoma. BMC Cancer, 2006, 6, 131.	1.1	29
256	Functional Imaging Signature of Patients Presenting with Polycythemia/Paraganglioma Syndromes. Journal of Nuclear Medicine, 2017, 58, 1236-1242.	2.8	29
257	Anthracyclines suppress pheochromocytoma cell characteristics, including metastasis, through inhibition of the hypoxia signaling pathway. Oncotarget, 2017, 8, 22313-22324.	0.8	29
258	Therapeutic Targeting ofSDHB-Mutated Pheochromocytoma/Paraganglioma with Pharmacologic Ascorbic Acid. Clinical Cancer Research, 2020, 26, 3868-3880.	3.2	29
259	Quantitative 18F-DOPA PET/CT in pheochromocytoma: the relationship between tumor secretion and its biochemical phenotype. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 278-282.	3.3	28
260	Stressor-Specific Activation of Catecholaminergic Systems: Implications for Stress-Related Hypothalamic-Pituitary-Adrenocortical Responses. Advances in Pharmacology, 1997, 42, 561-564.	1.2	27
261	Low Sensitivity of Glucagon Provocative Testing for Diagnosis of Pheochromocytoma. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 238-245.	1.8	27
262	The Evolving Role of Succinate in Tumor Metabolism: An ¹⁸F-FDGâ€“Based Study. Journal of Nuclear Medicine, 2017, 58, 1749-1755.	2.8	27
263	18F-FDOPA PET/CT Imaging of MAX-Related Pheochromocytoma. Journal of Clinical Endocrinology and Metabolism, 2018, 103, 1574-1582.	1.8	27
264	Continued Tumor Reduction of Metastatic Pheochromocytoma/Paraganglioma Harboring Succinate Dehydrogenase Subunit B Mutations with Cyclical Chemotherapy. Cellular and Molecular Neurobiology, 2018, 38, 1099-1106.	1.7	27
265	Successful Second-Line Metronomic Temozolomide in Metastatic Paraganglioma: Case Reports and Review of the Literature. Clinical Medicine Insights: Oncology, 2018, 12, 117955491876336.	0.6	27
266	Differential Expression of Erythropoietin and Its Receptor in von Hippel-Lindau-Associated and Multiple Endocrine Neoplasia Type 2-Associated Pheochromocytomas. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 3747-3751.	1.8	26
267	Leptin concentrations in the abdominal subcutaneous adipose tissue of patients with anorexia nervosa assessed by in vivo microdialysis. Regulatory Peptides, 2005, 128, 63-68.	1.9	26
268	Determinants of Central Sympathetic Activation in Spontaneous Primary Subarachnoid Hemorrhage. Neurocritical Care, 2012, 16, 381-388.	1.2	26
269	Somatic mosaicism of EPAS1 mutations in the syndrome of paraganglioma and somatostatinoma associated with polycythemia. Human Genome Variation, 2015, 2, 15053.	0.4	26
270	Pheochromocytoma: Gasping for Air. Hormones and Cancer, 2015, 6, 191-205.	4.9	26

#	Article	IF	Citations
271	The microenvironment induces collective migration in SDHB-silenced mouse pheochromocytoma spheroids. Endocrine-Related Cancer, 2017, 24, 555-564.	1.6	26
272	Choice of biochemical test for diagnosis of pheochromocytoma: Validation of plasma metanephrines. Current Hypertension Reports, 2002, 4, 250-255.	1.5	25
273	Hypotension in a Woman with a Metastatic Dopamine-Secreting Carotid Body Tumor. Endocrine Practice, 2003, 9, 310-314.	1.1	25
274	Overexpression of Interleukin-13 Receptor-Î±2 in Neuroendocrine Malignant Pheochromocytoma: A Novel Target for Receptor Directed Anti-Cancer Therapy. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 2952-2957.	1.8	25
275	Pathological and Genetic Characterization of Bilateral Adrenomedullary Hyperplasia in a Patient with Germline MAX Mutation. Endocrine Pathology, 2017, 28, 302-307.	5.2	25
276	Postoperative Management in Patients with Pheochromocytoma and Paraganglioma. Cancers, 2019, 11, 936.	1.7	25
277	Phosphoprotein-based biomarkers as predictors for cancer therapy. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 18401-18411.	3.3	25
278	Succinate Mediates Tumorigenic Effects via Succinate Receptor 1: Potential for New Targeted Treatment Strategies in Succinate Dehydrogenase Deficient Paragangliomas. Frontiers in Endocrinology, 2021, 12, 589451.	1.5	25
279	Somatostatin Receptors and Analogs in Pheochromocytoma and Paraganglioma: Old Players in a New Precision Medicine World. Frontiers in Endocrinology, 2021, 12, 625312.	1.5	25
280	INCREASED PLASMA NOREPINEPHRINE CONCENTRATION IN CATS WITH INTERSTITIAL CYSTITIS. Journal of Urology, 2001, 165, 2051-2054.	0.2	25
281	A high rate of modestly elevated plasma normetanephrine in a population referred for suspected PPGL when measured in a seated position. European Journal of Endocrinology, 2019, 181, 301-309.	1.9	25
282	Diagnostic Localization of Malignant Bladder Pheochromocytoma Using 6-[18 F]Fluorodopamine Positron Emission Tomography. Journal of Urology, 2003, 169, 274-275.	0.2	24
283	Transcriptional Regulation of Phenylethanolamine N-Methyltransferase in Pheochromocytomas from Patients with von Hippel-Lindau Syndrome and Multiple Endocrine Neoplasia Type 2. Annals of the New York Academy of Sciences, 2006, 1073, 241-252.	1.8	24
284	Diagnosis and preoperative imaging of multiple endocrine neoplasia type 2: current status and future directions. Clinical Endocrinology, 2014, 81, 317-328.	1.2	24
285	Association of urinary bladder paragangliomas with germline mutations in the SDHB and VHL genes. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 167.e13-167.e20.	0.8	24
286	The role of GSK3 and its reversal with GSK3 antagonism in everolimus resistance. Endocrine-Related Cancer, 2018, 25, 893-908.	1.6	24
287	Synergistic Highly Potent Targeted Drug Combinations in Different Pheochromocytoma Models Including Human Tumor Cultures. Endocrinology, 2019, 160, 2600-2617.	1.4	24
288	Impact of Extrinsic and Intrinsic Hypoxia on Catecholamine Biosynthesis in Absence or Presence of Hif2Î± in Pheochromocytoma Cells. Cancers, 2019, 11, 594.	1.7	24

#	Article	IF	Citations
289	Anti-Cancer Potential of MAPK Pathway Inhibition in Paragangliomasâ€“Effect of Different Statins on Mouse Pheochromocytoma Cells. PLoS ONE, 2014, 9, e97712.	1.1	24
290	Chronic blockade of nitric oxide synthesis elevates plasma levels of catecholamines and their metabolites at rest and during stress in rats. Neurochemical Research, 1997, 22, 995-1001.	1.6	23
291	Usefulness of Standardized Uptake Values for Distinguishing Adrenal Glands with Pheochromocytoma from Normal Adrenal Glands by Use of 6-18F-Fluorodopamine PET. Journal of Nuclear Medicine, 2007, 48, 1940-1944.	2.8	23
292	Candidate Genes Associated With Malignant Pheochromocytomas by Genome-Wide Expression Profiling. Annals of Surgery, 2009, 250, 983-990.	2.1	23
293	Current and Future Trends in the Anatomical and Functional Imaging of Head and Neck Paragangliomas. Seminars in Nuclear Medicine, 2013, 43, 462-473.	2.5	23
294	Targeting Heat Shock Protein 90 for the Treatment of Malignant Pheochromocytoma. PLoS ONE, 2013, 8, e56083.	1.1	23
295	Ocular Manifestations of Hypoxia-Inducible Factor-2Î± Paraganglioma-Somatostatinoma-Polycythemia Syndrome. Ophthalmology, 2014, 121, 2291-2293.	2.5	23
296	Carney triad, SDH-deficient tumors, and Sdhb+/â^' mice share abnormal mitochondria. Endocrine-Related Cancer, 2015, 22, 345-352.	1.6	23
297	Pendrin localizes to the adrenal medulla and modulates catecholamine release. American Journal of Physiology - Endocrinology and Metabolism, 2015, 309, E534-E545.	1.8	23
298	Primary fibroblast co-culture stimulates growth and metabolism in Sdhb-impaired mouse pheochromocytoma MTT cells. Cell and Tissue Research, 2018, 374, 473-485.	1.5	23
299	Optimizing Genetic Workup in Pheochromocytoma and Paraganglioma by Integrating Diagnostic and Research Approaches. Cancers, 2019, 11, 809.	1.7	23
300	Metabolomics, machine learning and immunohistochemistry to predict succinate dehydrogenase mutational status in phaeochromocytomas and paragangliomas. Journal of Pathology, 2020, 251, 378-387.	2.1	23
301	Targeting NRF2-Governed Glutathione Synthesis for SDHB-Mutated Pheochromocytoma and Paraganglioma. Cancers, 2020, 12, 280.	1.7	23
302	Expression of the noradrenaline transporter and phenylethanolamine N-methyltransferase in normal human adrenal gland and phaeochromocytoma. Cell and Tissue Research, 2005, 322, 443-453.	1.5	22
303	Pheochromocytoma. Annals of the New York Academy of Sciences, 2008, 1148, 462-468.	1.8	22
304	Characterization of two mouse models of metastatic pheochromocytoma using bioluminescence imaging. Cancer Letters, 2012, 316, 46-52.	3.2	22
305	A Transgenic Mouse Model of Pacakâ€“Zhuang Syndrome with An Epas1 Gain-of-Function Mutation. Cancers, 2019, 11, 667.	1.7	22
306	The 3PAs: An Update on the Association of Pheochromocytomas, Paragangliomas, and Pituitary Tumors. Hormone and Metabolic Research, 2019, 51, 419-436.	0.7	22

#	Article	IF	Citations
307	What Have We Learned from Molecular Biology of Paragangliomas and Pheochromocytomas?. Endocrine Pathology, 2021, 32, 134-153.	5.2	22
308	Comprehensive review of evaluation and management of cardiac paragangliomas. Heart, 2020, 106, 1202-1210.	1.2	22
309	The Significant Reduction or Complete Eradication of Subcutaneous and Metastatic Lesions in a Pheochromocytoma Mouse Model after Immunotherapy Using Mannan-BAM, TLR Ligands, and Anti-CD40. Cancers, 2019, 11, 654.	1.7	21
310	Germline SUCLG2 Variants in Patients With Pheochromocytoma and Paraganglioma. Journal of the National Cancer Institute, 2022, 114, 130-138.	3.0	21
311	Drugs and pheochromocytoma--don't be fooled by every elevated metanephrine. New England Journal of Medicine, 2011, 364, 2268-70.	13.9	21
312	The Incidentally Discovered Adrenal Mass. New England Journal of Medicine, 2007, 356, 2005-2006.	13.9	20
313	The Use of Functional Imaging in a Patient with Head and Neck Paragangliomas. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 481-482.	1.8	20
314	Urinary Bladder Paragangliomas. American Journal of Surgical Pathology, 2015, 39, 1488-1492.	2.1	20
315	HIF2A gain-of-function mutations detected in duodenal gangliocytic paraganglioma. Endocrine-Related Cancer, 2016, 23, L13-L16.	1.6	20
316	18F-fluorodihydroxyphenylalanine PET/CT in pheochromocytoma and paraganglioma: relation to genotype and amino acid transport system L. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 812-821.	3.3	20
317	An assessment of biochemical tests for the diagnosis of pheochromocytoma. Nature Clinical Practice Endocrinology and Metabolism, 2007, 3, 744-745.	2.9	19
318	Exercise-induced nausea and vomiting: another sign and symptom of pheochromocytoma and paraganglioma. Endocrine, 2010, 37, 403-407.	1.1	19
319	Integrated Whole-Body PET/MRI With 18F-FDG, 18F-FDOPA, and 18F-FDA in Paragangliomas in Comparison With PET/CT. Clinical Nuclear Medicine, 2014, 39, 243-250.	0.7	19
320	Pathology of Human Pheochromocytoma and Paraganglioma Xenografts in NSG Mice. Endocrine Pathology, 2017, 28, 2-6.	5.2	19
321	A Reduction in Pten Tumor Suppressor Activity Promotes ErbB-2-Induced Mouse Prostate Adenocarcinoma Formation through the Activation of Signaling Cascades Downstream of PDK1. American Journal of Pathology, 2009, 174, 2051-2060.	1.9	18
322	Renaissance of 18F-FDG Positron Emission Tomography in the Imaging of Pheochromocytoma/Paraganglioma. Journal of Clinical Endocrinology and Metabolism, 2014, 99, 2337-2339.	1.8	18
323	Somatic gain-of-function HIF2A mutations in sporadic central nervous system hemangioblastomas. Journal of Neuro-Oncology, 2016, 126, 473-481.	1.4	18
324	Pheochromocytoma and Paraganglioma Patients With Poor Survival Often Show Brown Adipose Tissue Activation. Journal of Clinical Endocrinology and Metabolism, 2020, 105, 1176-1185.	1.8	18

#	Article	IF	Citations
325	Determinants of disease-specific survival in patients with and without metastatic pheochromocytoma and paraganglioma. European Journal of Cancer, 2022, 169, 32-41.	1.3	18
326	ErbB-2 Induces Bilateral Adrenal Pheochromocytoma Formation in Mice. Cell Cycle, 2007, 6, 1946-1950.	1.3	17
327	Malignant paraganglioma associated with succinate dehydrogenase subunit B in an 8-year-old child: the age of first screening?. Pediatric Nephrology, 2009, 24, 1239-1242.	0.9	17
328	Association between acute sympathetic response, early onset vasospasm, and delayed vasospasm following spontaneous subarachnoid hemorrhage. Journal of Clinical Neuroscience, 2014, 21, 256-262.	0.8	17
329	Lack of utility of SDHB mutation testing in adrenergic metastatic phaeochromocytoma. European Journal of Endocrinology, 2015, 172, 89-95.	1.9	17
330	New insights on the pathogenesis of paraganglioma and pheochromocytoma. F1000Research, 2018, 7, 1500.	0.8	17
331	Gender-related differences in the clinical presentation of malignant and benign pheochromocytoma. Endocrine, 2008, 34, 96-100.	1.1	16
332	Hypoxia-Inducible Factor 2Î± Mutation-Related Paragangliomas Classify as Discrete Pseudohypoxic Subcluster. Neoplasia, 2016, 18, 567-576.	2.3	16
333	HIF-2alpha: Achilles' heel of pseudohypoxic subtype paraganglioma and other related conditions. European Journal of Cancer, 2017, 86, 1-4.	1.3	16
334	Deletion of the von Hippel-Lindau Gene in Hemangioblasts Causes Hemangioblastoma-like Lesions in Murine Retina. Cancer Research, 2018, 78, 1266-1274.	0.4	16
335	A xenograft and cell line model of SDH-deficient pheochromocytoma derived from Sdhb+/â˜ rats. Endocrine-Related Cancer, 2020, 27, 337-354.	1.6	16
336	Regulation of Peripheral Catecholamine Responses to Acute Stress in Young Adult and Aged F-344 Rats. Stress, 1997, 2, 113-122.	0.8	15
337	Cardiac Uptake-1 Inhibition by High Circulating Norepinephrine Levels in Patients with Pheochromocytoma. Hypertension, 2004, 43, 1227-1232.	1.3	15
338	Metastasis-associated gene expression profile of liver and subcutaneous lesions derived from mouse pheochromocytoma cells. Molecular Carcinogenesis, 2008, 47, 245-251.	1.3	15
339	Unexplained Symptomatic Paroxysmal Hypertension in Pseudopheochromocytoma. Annals of the New York Academy of Sciences, 2008, 1148, 469-478.	1.8	15
340	Tyrosine hydroxylase, chromogranin A, and steroidogenic acute regulator as markers for successful separation of human adrenal medulla. Cell and Tissue Research, 2010, 340, 607-612.	1.5	15
341	Comparison of clinical and imaging features in succinate dehydrogenase-positive versus sporadic paragangliomas. Surgery, 2011, 150, 1186-1193.	1.0	15
342	Plasmaâ€free vs deconjugated metanephrines for diagnosis of phaeochromocytoma. Clinical Endocrinology, 2013, 79, 476-483.	1.2	15

#	Article	IF	Citations
343	Combination of 13-Cis Retinoic Acid and Lovastatin: Marked Antitumor Potential In Vivo in a Pheochromocytoma Allograft Model in Female Athymic Nude Mice. Endocrinology, 2014, 155, 2377-2390.	1.4	15
344	Preoperative Imaging Features are Associated with Surgical Complications Following Carotid Body Tumor Resection. World Journal of Surgery, 2015, 39, 2084-2089.	0.8	15
345	18F-DOPA: the versatile radiopharmaceutical. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 1187-1189.	3.3	15
346	A novel splicing site IRP1 somatic mutation in a patient with pheochromocytoma and JAK2V617F positive polycythemia vera: a case report. BMC Cancer, 2018, 18, 286.	1.1	15
347	Preoperative 18F-FDG PET/CT in Pheochromocytomas and Paragangliomas Allows for Precision Surgery. Annals of Surgery, 2019, 269, 741-747.	2.1	15
348	Characteristic CT features of pheochromocytomas - probability model calculation tool based on a multicentric study. Biomedical Papers of the Medical Faculty of the University Palacký, Olomouc, Czechoslovakia, 2019, 163, 212-219.	0.2	15
349	Characteristics of Blood Pressure in Pheochromocytoma. Annals of the New York Academy of Sciences, 2006, 1073, 86-93.	1.8	14
350	Proteomic profiling of von Hippelâ€“Lindau syndrome and multiple endocrine neoplasia type 2 pheochromocytomas reveals different expression of chromogranin B. Endocrine-Related Cancer, 2007, 14, 463-471.	1.6	14
351	Neuropeptide Y expression in phaeochromocytomas: relative absence in tumours from patients with von Hippelâ€“Lindau syndrome. Journal of Endocrinology, 2007, 193, 225-233.	1.2	14
352	Cytocidal Activities of Topoisomerase 1 Inhibitors and 5-Azacytidine against Pheochromocytoma/Paraganglioma Cells in Primary Human Tumor Cultures and Mouse Cell Lines. PLoS ONE, 2014, 9, e87807.	1.1	14
353	Genetics, Diagnosis, and Management of Medullary Thyroid Carcinoma and Pheochromocytoma/Paraganglioma. Endocrine Practice, 2014, 20, 176-187.	1.1	14
354	Application and Dosimetric Requirements for Gallium-68â€“labeled Somatostatin Analogues in Targeted Radionuclide Therapy for Gastroenteropancreatic Neuroendocrine Tumors. PET Clinics, 2015, 10, 477-486.	1.5	14
355	Nuclear Medicine in Cancer Theranostics: Beyond the Target. Journal of Nuclear Medicine, 2016, 57, 1659-1660.	2.8	14
356	Are patients with hormonally functional phaeochromocytoma and paraganglioma initially receiving a proper adrenoceptor blockade? A retrospective cohort study. Clinical Endocrinology, 2016, 85, 62-69.	1.2	14
357	A Previously Unrecognized Monocytic Component of Pheochromocytoma and Paraganglioma. Endocrine Pathology, 2019, 30, 90-95.	5.2	14
358	Why Take the Risk? We Only Live Once: The Dangers Associated with Neglecting a Pre-Operative Alpha Adrenoceptor Blockade in Pheochromocytoma Patients. Endocrine Practice, 2019, 25, 106-108.	1.1	14
359	Long intergenic noncoding RNA profiles of pheochromocytoma and paraganglioma: A novel prognostic biomarker. International Journal of Cancer, 2020, 146, 2326-2335.	2.3	14
360	Developmental vascular malformations in EPAS1 gain-of-function syndrome. JCI Insight, 2021, 6, .	2.3	14

#	Article	IF	Citations
361	Systemic Radiopharmaceutical Therapy of Pheochromocytoma and Paraganglioma. Journal of Nuclear Medicine, 2021, 62, 1192-1199.	2.8	14
362	Usefulness of [18F]-DA and [18F]-DOPA for PET imaging in a mouse model of pheochromocytoma. Nuclear Medicine and Biology, 2012, 39, 215-226.	0.3	13
363	Diagnostic Imaging of Pheochromocytoma. , 2003, 31, 107-120.		12
364	Counseling patients with succinate dehydrogenase subunit defects: genetics, preventive guidelines, and dealing with uncertainty. Journal of Pediatric Endocrinology and Metabolism, 2014, 27, 837-44.	0.4	12
365	Inhibitory Effect of the Noncamptothecin Topoisomerase I Inhibitor LMP-400 on Female Mice Models and Human Pheochromocytoma Cells. Endocrinology, 2015, 156, 4094-4104.	1.4	12
366	Emerging role of dopamine in neovascularization of pheochromocytoma and paraganglioma. FASEB Journal, 2017, 31, 2226-2240.	0.2	12
367	Sporadic Primary Pheochromocytoma: A Prospective Intraindividual Comparison of Six Imaging Tests (CT, MRI, and PET/CT Using ⁶⁸Ga-DOTATATE, FDG, ¹⁸F-FDOPA, and) Tj ETQq1 1 0.784314 rgBT /Overlock 10	1.4	12
368	Personalized drug testing in human pheochromocytoma/paraganglioma primary cultures. Endocrine-Related Cancer, 2022, 29, 285-306.	1.6	12
369	Head/neck paragangliomas: focus on tumor location, mutational status and plasma methoxytyramine. Endocrine-Related Cancer, 2022, 29, 213-224.	1.6	12
370	Triiodothyronine attenuates estradiol-induced increases in dopamine D-2 receptor number in rat anterior pituitary. Brain Research, 1996, 712, 148-152.	1.1	11
371	Hyperinsulinemia and Sympathoadrenal System Activity in the Rat. Annals of the New York Academy of Sciences, 1997, 827, 118-134.	1.8	11
372	Management of Malignant Pheochromocytoma. , 2002, 12, 291-299.		11
373	Anatomical and Functional Imaging of Tumors in Animal Models: Focus on Pheochromocytoma. Annals of the New York Academy of Sciences, 2006, 1073, 392-404.	1.8	11
374	CSF Catecholamine Profile in Subarachnoid Hemorrhage Patients with Neurogenic Cardiomyopathy. Neurocritical Care, 2011, 14, 401-406.	1.2	11
375	Metanephrines for Evaluating Palpitations and Flushing. JAMA - Journal of the American Medical Association, 2017, 318, 385.	3.8	11
376	Prospective evaluation of ⁶⁸Gaâ€<scp>DOTATATE PET</scp>/<scp>CT</scp> in limited disease neuroendocrine tumours and/or elevated serum neuroendocrine biomarkers. Clinical Endocrinology, 2018, 89, 155-163.	1.2	11
377	A Clinical Roadmap to Investigate the Genetic Basis of Pediatric Pheochromocytoma: Which Genes Should Physicians Think About?. International Journal of Endocrinology, 2018, 2018, 1-14.	0.6	11
378	Coley's immunotherapy revived: Innate immunity as a link in priming cancer cells for an attack by adaptive immunity. Seminars in Oncology, 2019, 46, 385-392.	0.8	11

#	Article	IF	Citations
379	MicroRNA-210 May Be a Preoperative Biomarker of Malignant Pheochromocytomas and Paragangliomas. Journal of Surgical Research, 2019, 243, 1-7.	0.8	11
380	Nonmosaic somatic HIF2A mutations associated with late onset polycythemiaâ€paraganglioma syndrome: Newly recognized subclass of polycythemiaâ€paraganglioma syndrome. Cancer, 2019, 125, 1258-1266.	2.0	11
381	Induction of Immune Response against Metastatic Tumors via Vaccination of Mannanâ€BAM, TLR Ligands, and Antiâ€CD40 Antibody (MBTA). Advanced Therapeutics, 2020, 3, 2000044.	1.6	11
382	Targeting pheochromocytoma/paraganglioma with polyamine inhibitors. Metabolism: Clinical and Experimental, 2020, 110, 154297.	1.5	11
383	Variants and Pitfalls of PET/CT in Neuroendocrine Tumors. Seminars in Nuclear Medicine, 2021, 51, 519-528.	2.5	11
384	A New Concept of Unopposed Î²-Adrenergic Overstimulation in a Patient with Pheochromocytoma. Annals of Internal Medicine, 2005, 142, 1026.	2.0	11
385	Local sympathetic function in human skeletal muscle and adipose tissue assessed by microdialysis. Clinical Autonomic Research, 2002, 12, 13-19.	1.4	10
386	Phospho-mTOR is not upregulated in metastaticSDHBparagangliomas. European Journal of Clinical Investigation, 2013, 43, 970-977.	1.7	10
387	Total 18F-FDG PET/CT Metabolic Tumor Volume Is Associated With Postoperative Biochemical Response in Patients With Metastatic Pheochromocytomas and Paragangliomas. Annals of Surgery, 2016, 263, 582-587.	2.1	10
388	InÂvivo detection of catecholamines byÂmagnetic resonance spectroscopy: AÂpotential specific biomarker for the diagnosis of pheochromocytoma. Surgery, 2016, 159, 1231-1233.	1.0	10
389	Mass spectrometric quantification of salivary metanephrinesâ€"A study in healthy subjects. Clinical Biochemistry, 2016, 49, 983-988.	0.8	10
390	Leptomeningeal dissemination of a low-grade lumbar paraganglioma: case report. Journal of Neurosurgery: Spine, 2017, 26, 501-506.	0.9	10
391	Bortezomib Alone and in Combination With Salinosporamid A Induces Apoptosis and Promotes Pheochromocytoma Cell Death In Vitro and in Female Nude Mice. Endocrinology, 2017, 158, 3097-3108.	1.4	10
392	Blood collection in unstressed, conscious, and freely moving mice through implantation of catheters in the jugular vein: a new simplified protocol. Physiological Reports, 2018, 6, e13904.	0.7	10
393	RNA-Sequencing Analysis of Adrenocortical Carcinoma, Pheochromocytoma and Paraganglioma from a Pan-Cancer Perspective. Cancers, 2018, 10, 518.	1.7	10
394	Cardiometabolic risk factors and health behaviors in family caregivers. PLoS ONE, 2017, 12, e0176408.	1.1	10
395	Hypoxia potentiates the cytotoxic effect of piperlongumine in pheochromocytoma models. Oncotarget, 2016, 7, 40531-40545.	0.8	10
396	Potential therapeutic target for malignant paragangliomas: ATP synthase on the surface of paraganglioma cells. American Journal of Cancer Research, 2015, 5, 1558-70.	1.4	10

#	Article	IF	Citations
397	Utility of Plasma Free Metanephrines in Diagnosis of Factitious Pheochromocytoma. Endocrine Practice, 2006, 12, 568-571.	1.1	9
398	Animal Models of Pheochromocytoma Including NIH Initial Experience. Annals of the New York Academy of Sciences, 2006, 1073, 300-305.	1.8	9
399	High-Throughput Screening for the Identification of New Therapeutic Options for Metastatic Pheochromocytoma and Paraganglioma. PLoS ONE, 2014, 9, e90458.	1.1	9
400	Endocrine tumors associated with the vagus nerve. Endocrine-Related Cancer, 2016, 23, R371-R379.	1.6	9
401	Functional Imaging Experience in a Germline Fumarate Hydratase Mutationâ€“Positive Patient With Pheochromocytoma and Paraganglioma. AACE Clinical Case Reports, 2016, 2, e176-e181.	0.4	9
402	Determination of the unmetabolised 18F-FDG fraction by using an extension of simplified kinetic analysis method: clinical evaluation in paragangliomas. Medical and Biological Engineering and Computing, 2016, 54, 103-111.	1.6	9
403	Pseudopheochromocytoma. Endocrinology and Metabolism Clinics of North America, 2019, 48, 751-764.	1.2	9
404	Ivabradine in Catecholamine-Induced Tachycardia in a Patient with Paraganglioma. New England Journal of Medicine, 2019, 380, 1284-1286.	13.9	9
405	Eruption of Metastatic Paraganglioma After Successful Therapy with 177Lu/90Y-DOTATOC and 177Lu-DOTATATE. Nuclear Medicine and Molecular Imaging, 2019, 53, 223-230.	0.6	9
406	Prognostic and predictive value of nuclear imaging in endocrine oncology. Endocrine, 2020, 67, 9-19.	1.1	9
407	Role of 68Ga-DOTATATE PET/CT in a Case of SDHB-Related Pterygopalatine Fossa Paraganglioma Successfully Controlled with Octreotide. Nuclear Medicine and Molecular Imaging, 2020, 54, 48-52.	0.6	9
408	C-Terminal, but Not Intact, FGF23 and EPO Are Strongly Correlatively Elevated in Patients With Gain-of-Function Mutations in HIF2A: Clinical Evidence for EPO Regulating FGF23. Journal of Bone and Mineral Research, 2020, 36, 315-321.	3.1	9
409	Clinically Advanced Pheochromocytomas and Paragangliomas: A Comprehensive Genomic Profiling Study. Cancers, 2021, 13, 3312.	1.7	9
410	A novel liquid biopsy (NETest) identifies paragangliomas and pheochromocytomas with high accuracy. Endocrine-Related Cancer, 2021, 28, 731-744.	1.6	9
411	Chiari Malformation Type 1 in EPAS1-Associated Syndrome. International Journal of Molecular Sciences, 2019, 20, 2819.	1.8	8
412	GsÎ± deficiency in the dorsomedial hypothalamus leads to obesity, hyperphagia, and reduced thermogenesis associated with impaired leptin signaling. Molecular Metabolism, 2019, 25, 142-153.	3.0	8
413	Phaeochromocytoma â€" advances through science, collaboration and spreading the word. Nature Reviews Endocrinology, 2020, 16, 621-622.	4.3	8
414	A Clinical Challenge: Endocrine and Imaging Investigations of Adrenal Masses. Journal of Nuclear Medicine, 2021, 62, 26S-33S.	2.8	8

#	Article	IF	Citations
415	Differences in clinical presentation and management between pre- and postsurgical diagnoses of urinary bladder paraganglioma: is there clinical relevance? A systematic review. World Journal of Urology, 2022, 40, 385-390.	1.2	8
416	How do levels of (endogenous) glucocorticoids, interleukin-10 and interleukin-12 relate to multiple sclerosis relapse before, during and after pregnancy?. Clinical Endocrinology, 1999, 50, 818-819.	1.2	7
417	Combined corticotropin-releasing hormone and glucocorticoid deficiency does not enhance counterregulatory responses after recurrent hypoglycemia in mice. Metabolism: Clinical and Experimental, 2005, 54, 1259-1265.	1.5	7
418	Association between sympathetic response, neurogenic cardiomyopathy, and venous thromboembolization in patients with primary subarachnoid hemorrhage. Acta Neurochirurgica, 2013, 155, 1501-1510.	0.9	7
419	Molecular evaluation of a sporadic paraganglioma with concurrent IDH1 and ATRX mutations. Endocrine, 2018, 61, 216-223.	1.1	7
420	Genetic Determinants of Pheochromocytoma and Paraganglioma Imaging Phenotypes. Journal of Nuclear Medicine, 2020, 61, 643-645.	2.8	7
421	Mannan-BAM, TLR Ligands, Anti-CD40 Antibody (MBTA) Vaccine Immunotherapy: A Review of Current Evidence and Applications in Glioblastoma. International Journal of Molecular Sciences, 2021, 22, 3455.	1.8	7
422	Identification of Immune Cell Infiltration in Murine Pheochromocytoma during Combined Mannan-BAM, TLR Ligand, and Anti-CD40 Antibody-Based Immunotherapy. Cancers, 2021, 13, 3942.	1.7	7
423	Pheochromocytoma. Nature Clinical Practice Cardiovascular Medicine, 2008, 5, E1-E1.	3.3	7
424	Epidural anesthesia and hypotension in pheochromocytoma and paraganglioma. Endocrine-Related Cancer, 2020, 27, 519-527.	1.6	7
425	AN AGGRESSIVE TEMPORAL BONE SDHC PARAGANGLIOMA ASSOCIATED WITH INCREASED HIF-2Î± SIGNALING. Endocrine Practice, 2016, 22, 190-195.	1.1	6
426	Radiopharmaceuticals in paraganglioma imaging: too many members on board?. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 391-393.	3.3	6
427	Current expertsâ€™ views on precision nuclear medicine imaging of phaeochromocytoma and paraganglioma. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 2223-2224.	3.3	6
428	Gallbladder Paraganglioma Associated with SDHD Mutation: a Potential Pitfall on 18F-FDOPA PET Imaging. Nuclear Medicine and Molecular Imaging, 2019, 53, 144-147.	0.6	6
429	Phaeochromocytoma and pregnancy: looking towards better outcomes, less fear, and valuable recommendations. Lancet Diabetes and Endocrinology,the, 2021, 9, 2-3.	5.5	6
430	Functional significance of germline EPAS1 variants. Endocrine-Related Cancer, 2021, 28, 97-109.	1.6	6
431	Pediatric Metastatic Pheochromocytoma and Paraganglioma: Clinical Presentation and Diagnosis, Genetics, and Therapeutic Approaches. Frontiers in Endocrinology, 0, 13, .	1.5	6
432	Adenoviral Gene Transfer in Bovine Adrenomedullary and Murine Pheochromocytoma Cells: Potential Clinical and Therapeutic Relevance. Endocrinology, 2007, 148, 3900-3907.	1.4	5

#	Article	IF	Citations
433	Mitochondrial Localization of Human Recombinant Adenovirus: From Evolution to Gene Therapy. NeuroImmunoModulation, 2007, 14, 221-223.	0.9	5
434	Development and validation of a comprehensive mutation and deletion detection assay for SDHB, SDHC, and SDHD. Clinical Biochemistry, 2010, 43, 700-704.	0.8	5
435	Diagnostic Investigation of Lesions Associated with Succinate Dehydrogenase Defects. Hormone and Metabolic Research, 2019, 51, 414-418.	0.7	5
436	Neuraxial dysraphism in EPAS1-associated syndrome due to improper mesenchymal transition. Neurology: Genetics, 2020, 6, e414.	0.9	5
437	Mannan-BAM, TLR ligands, and anti-CD40 immunotherapy in established murine pancreatic adenocarcinoma: understanding therapeutic potentials and limitations. Cancer Immunology, Immunotherapy, 2021, 70, 3303-3312.	2.0	5
438	Identification of Isocitrate Dehydrogenase 2 (IDH2) Mutation in Carotid Body Paraganglioma. Frontiers in Endocrinology, 2021, 12, 731096.	1.5	5
439	The role of dopamine in methylene blue-mediated inhibition of estradiol benzoate-induced anterior pituitary hyperplasia in rats. Neuroscience Letters, 2001, 304, 194-198.	1.0	4
440	Double stable isotope ultra performance liquid chromatographic-tandem mass spectrometric quantification of tissue content and activity of phenylethanolamine N-methyltransferase, the crucial enzyme responsible for synthesis of epinephrine. Analytical and Bioanalytical Chemistry, 2013, 405, 1713-1719.	1.9	4
441	18F-FLT PET/CT in the Evaluation of Pheochromocytomas and Paragangliomas: A Pilot Study. Journal of Nuclear Medicine, 2015, 56, 1849-1854.	2.8	4
442	Implications of SDHB genetic testing in patients with sporadic pheochromocytoma. Langenbeck's Archives of Surgery, 2017, 402, 787-798.	0.8	4
443	Paraganglioma of the organ of Zuckerkandl associated with a somatic HIF2Î± mutation: A case report. Oncology Letters, 2017, 13, 1083-1086.	0.8	4
444	Mathematical modeling of disease dynamics in SDHB- and SDHD-related paraganglioma: Further step in understanding hereditary tumor differences and future therapeutic strategies. PLoS ONE, 2018, 13, e0201303.	1.1	4
445	Tumor multifocality with vagus nerve involvement as a phenotypic marker of SDHD mutation in patients with head and neck paragangliomas: A ¹⁸Fâ€FDOPA PET/CT study. Head and Neck, 2019, 41, 1565-1571.	0.9	4
446	Surgical Resection of Pheochromocytomas and Paragangliomas is Associated with Lower Cholesterol Levels. World Journal of Surgery, 2020, 44, 552-560.	0.8	4
447	Vascular Changes in the Retina and Choroid of Patients With EPAS1 Gain-of-Function Mutation Syndrome. JAMA Ophthalmology, 2020, 138, 148.	1.4	4
448	Clinical manifestations of Pacakâ€Zhuang syndrome in a male pediatric patient. Pediatric Blood and Cancer, 2020, 67, e28096.	0.8	4
449	Case Report: Primary Hypothyroidism Associated With Lutetium 177-DOTATATE Therapy for Metastatic Paraganglioma. Frontiers in Endocrinology, 2020, 11, 587065.	1.5	4
450	Deep Membrane Proteome Profiling Reveals Overexpression of Prostate-Specific Membrane Antigen (PSMA) in High-Risk Human Paraganglioma and Pheochromocytoma, Suggesting New Theranostic Opportunity. Molecules, 2021, 26, 6567.	1.7	4

#	Article	IF	Citations
451	18F-FDOPA PET/CT accurately identifies MEN1-associated pheochromocytoma. Endocrinology, Diabetes and Metabolism Case Reports, 2020, 2020, .	0.2	4
452	A novel germline gain-of-function HIF2A mutation in hepatocellular carcinoma with polycythemia. Aging, 2020, 12, 5781-5791.	1.4	4
453	Sympathoneural and skeletal muscle contributions to plasma DOPA responses in pithed rats. Journal of the Autonomic Nervous System, 1991, 35, 169-174.	1.9	3
454	Genomic Medicine. Annals of the New York Academy of Sciences, 2002, 970, 177-192.	1.8	3
455	Pheochromocytoma: Unmasking the Chameleon. , 2013, , 123-148.		3
456	Precision Medicine in Adrenal Disorders: the Next Generation. Endocrine Practice, 2017, 23, 672-679.	1.1	3
457	Relevant Discordance Between 68Ga-DOTATATE and 68Ga-DOTANOC in SDHB-Related Metastatic Paraganglioma. Clinical Nuclear Medicine, 2017, 42, 211-213.	0.7	3
458	Reply: 68Ga-DOTATATE PET/CT Versus MRI: Why the Comparison of 68Ga-DOTATATE PET/CT to an Appropriate MRI Protocol Is Essential. Journal of Nuclear Medicine, 2017, 58, 185-185.	2.8	3
459	Successful induction therapy with sequential CVD followed by high-dose lanreotide in for metastatic SDHB paraganglioma: Case report. Journal of Clinical and Translational Endocrinology: Case Reports, 2018, 7, 8-13.	0.4	3
460	Exploring the link between tumour metabolism and succinate dehydrogenase deficiency: A ¹⁸Fâ€FDOPA PET/CT study in head and neck paragangliomas. Clinical Endocrinology, 2019, 91, 879-884.	1.2	3
461	Imaging of Small Intestine Neuroendocrine Neoplasms: Is SSTR PET the Holy Grail?. Journal of Nuclear Medicine, 2021, 62, 1347-1348.	2.8	3
462	Reactive Oxygen Species: A Promising Therapeutic Target for SDHx-Mutated Pheochromocytoma and Paraganglioma. Cancers, 2021, 13, 3769.	1.7	3
463	Quantitative biomarkers allow the diagnosis of head and neck paraganglioma on multiparametric MRI. European Journal of Radiology, 2021, 143, 109911.	1.2	3
464	Supportive management of patients with pheochromocytoma/paraganglioma undergoing noninvasive treatment. Current Opinion in Endocrinology, Diabetes and Obesity, 2022, 29, 294-301.	1.2	3
465	Effects of hypercortisolemia or hyperinsulinemia on neurochemical indices of catecholamine release and synthesis in conscious rats. Journal of the Autonomic Nervous System, 1995, 54, 104-112.	1.9	2
466	Familial pheochromocytomas and paragangliomas associated with mutations of the succinate dehydrogenase genes. Expert Review of Endocrinology and Metabolism, 2007, 2, 399-406.	1.2	2
467	Multidisciplinary management of locally advanced and widely metastatic paraganglioma in a patient with lifeâ€threatening compressive symptoms. Head and Neck, 2015, 37, E205-8.	0.9	2
468	Pheochromocytoma and Paraganglioma Syndromes. , 2015, , 449-454.		2

#	Article	IF	Citations
469	Rapidly Growing Chest Wall Mass in a Case of Sporadic Metastatic Paraganglioma. Clinical Nuclear Medicine, 2016, 41, 399-400.	0.7	2
470	PET Imaging for Endocrine Malignancies: From Woe to Go. Journal of Nuclear Medicine, 2017, 58, 878-880.	2.8	2
471	Pheochromocytoma/Paraganglioma: Update on Diagnosis and Management. Contemporary Endocrinology, 2018, , 261-310.	0.3	2
472	Some Considerations in Treating Malignant Head and Neck Paragangliomas. JAMA Otolaryngology - Head and Neck Surgery, 2020, 146, 209.	1.2	2
473	Diagnostic Accuracy of Salivary Metanephrines in Pheochromocytomas and Paragangliomas. Clinical Chemistry, 2021, 67, 1090-1097.	1.5	2
474	Pheochromocytoma Resection: The Rule of Surgical Divergence. AACE Clinical Case Reports, 2016, 2, e78-e79.	0.4	2
475	Functional Imaging of Neuroendocrine Tumors: Stacking the Odds in a Patientâ€™s Favor. Journal of Clinical Endocrinology and Metabolism, 2022, 107, e3953-e3954.	1.8	2
476	Uncommon Endocrine Tumors in Children and Adolescents. , 2006, , 775-797.		1
477	When is a phaeo not a phaeo? Depression in an adolescent leading to a phaeochromocytomaâ€like biochemical profile. Clinical Endocrinology, 2011, 75, 567-568.	1.2	1
478	Multitracer PET imaging of bone metastases from paraganglioma: peripheral halo of uptake on 18F-FLT PET mismatching with central uptake of 18F-FDOPA, 18F-fluorodopamine, and 18F-FDG. European Journal of Nuclear Medicine and Molecular Imaging, 2013, 40, 1928-1929.	3.3	1
479	A Necessity, not a Second Thought: Pre-Operative Alpha-Adrenoceptor Blockade in Pheochromocytoma Patients. Endocrine Practice, 2019, 25, 200-201.	1.1	1
480	Molecular Imaging in the Era of Precision Medicine: Paraganglioma as a Template for Understanding Multiple Levels of Analysis. Journal of Nuclear Medicine, 2020, 61, 646-648.	2.8	1
481	A long noncoding RNAâ€“microRNA expression signature predicts metastatic signature in pheochromocytomas and paragangliomas. Endocrine, 2021, , 1.	1.1	1
482	The Global Reading Room: Nuclear Medicine Imaging of Suspected Paraganglioma. American Journal of Roentgenology, 2021, 217, 1008-1009.	1.0	1
483	Pheochromocytoma Hypertensive Crisis. , 2014, , 139-147.		1
484	Response to Letter to the Editor by Dullaart etÂal.. Clinical Endocrinology, 2010, 72, 569-570.	1.2	0
485	Commentary. Clinical Chemistry, 2013, 59, 1565-1565.	1.5	0
486	Uncommon spreading of primary malignant paraganglioma in a patient with SDHB mutation. Case Reports in Internal Medicine, 2016, 4, 63.	0.0	0

#	Article	IF	Citations
487	The Author's Reply: inappropriate adrenoreceptor blockade prior to pheochromocytoma removal â€“ â€˜A timely reappraisalâ€™. Clinical Endocrinology, 2016, 85, 990-991.	1.2	0
488	Radionuclide Imaging of Head and Neck Paragangliomas. , 2017, , 269-294.		0
489	Radionuclide Imaging of Chromaffin Cell Tumors. , 2017, , 295-319.		0
490	Recent advances in the imaging of pheochromocytomas and paragangliomas. International Journal of Endocrine Oncology, 2017, 4, 137-144.	0.4	0
491	Management of Pheochromocytoma and Paraganglioma. , 2017, , 179-206.		0
492	Imaging Modalities for Pheochromocytoma and Paraganglioma. , 2017, , 125-138.		0
493	New Challenges in Nuclear Endocrinology. Journal of Nuclear Medicine, 2018, 59, 573-574.	2.8	0
494	SDHD Gene Mutations: Looking Beyond Head and Neck Tumors. AACE Clinical Case Reports, 2018, 4, 186-190.	0.4	0
495	More on Ivabradine in Tachycardia with Paraganglioma. New England Journal of Medicine, 2019, 380, 2590-2590.	13.9	0
496	Pheochromocytoma Hypertensive Crisis. Contemporary Endocrinology, 2021, , 137-145.	0.3	0
497	Somatic Mosaicism of EPAS1 Mutations in Pacak-Zhuang Syndrome. Endocrine Practice, 2022, , .	1.1	0